Benzinga's Top Pre-Market Losers
October 18, 2013 at 08:15 AM EDT
Ariad Pharmaceuticals (NASDAQ: ARIA ) shares fell 30% to $3.15 in the pre-market trading after the company announced discontinuation of the Phase 3 EPIC trial of Iclusig. Acacia Research (NASDAQ: ACTG ) shares dropped 17.02% to $16.28 in pre-market trading after the company reported Q3 results. Stephens downgraded the
